Enhanced effect of connexin 43 on cisplatin-induced cytotoxicity in mesothelioma cells

Journal of Pharmacological Sciences

Volumn 110, Issue 4, 2009, Pages 466-475

  Sato, Hiromi ^a,b   Iwata, Hiroki ^a   Takano, Yasuyuki ^a,b   Yamada, Ryota ^a   Okuzawa, Hiroko ^a   Nagashima, Yoji ^c   Yamaura, Katsunori ^a   Ueno, Koichi ^a   Yano, Tomohiro ^b  

^a CHIBA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Cisplatin; Connexin; Drug resistance; Mesothelioma

Indexed keywords

CISPLATIN; CONNEXIN 43;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COMMUNICATION; CELL LINE; CELL VIABILITY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GAP JUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CONNEXIN 43; DRUG RESISTANCE, NEOPLASM; GAP JUNCTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; PROTO-ONCOGENE PROTEINS PP60(C-SRC); TRANSFECTION; UP-REGULATION;

EID: 68849123924     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08327FP     Document Type: Article

References (36)

1. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest. 1995;107: 345S-350S.
2. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;13:66S-73S. (Pubitemid 28051738)
3. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25-30. (Pubitemid 29022374)
4. van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86:342-345. (Pubitemid 34187648)
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;15:2636-2644. (Pubitemid 46606305)
6. Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V. Connexins and their channels in cell growth and cell death. Cell Signal. 2006;18:592-600. (Pubitemid 43113290)
7. Mesnil M. Connexins and cancer. Biol Cell. 2002;94:493-500.
8. Fujimoto E, Yano T, Sato H, Hagiwara K, Yamasaki H, Shirai S, et al. Cytotoxic effect of the Her-2/Her-1 inhibitor PKI-166 on renal cancer cells expressing the connexin 32 gene. J Pharmacol Sci. 2005;97:294-298. (Pubitemid 40410271)
9. Fujimoto E, Sato H, Nagashima Y, Negishi E, Shirai S, Fukumoto K, et al. A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells. Life Sci. 2005;76:2711-2720. (Pubitemid 40409503)
10. Fujimoto E, Sato H, Shirai S, Nagashima Y, Fukumoto K, Hagiwara H, et al. Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene. 2005;24: 3684-3690. (Pubitemid 40756238)
11. Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, et al. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog. 2007; 46:215-224. (Pubitemid 46399520)
12. Hagaiwara H, Sato H, Shirai S, Kobayashi S, Fukumoto K, Ishida T, et al. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells. Life Sci. 2006;78:2249-2254.
13. Sato H, Hagiwara H, Senba H, Fukumoto K, Nagashima Y, Yamasaki H, et al. The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma. Mol Carcinog. 2008;47:403-409. (Pubitemid 351822298)
14. Linnainmaa K, Pelin K, Vanhala E, Tuomi T, Piccoli C, Fitzgerald DJ, et al. Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells. Carcinogenesis. 1993;14:1597-1602. (Pubitemid 23249365)
15. Pelin K, Hirvonen A, Linnainmaa K. Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells. Carcinogenesis. 1994;15: 2673-2675. (Pubitemid 24343711)
16. Vinken M, De Rop E, Decrock E, De Vuyst E, Leybaert L, Vanhaecke T, et al. Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet? Biochim Biophys Acta. 2009;1795:53-61.
17. Loo LW, Berestecky JM, Kanemitsu MY, Lau AF. pp60src-mediated phosphorylation of connexin 43, a gap junction protein. J Biol Chem. 1995;270:12751-12761.
18. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358. (Pubitemid 36791891)
19. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007;6: 1962-1972. (Pubitemid 47052486)
20. Giepmans BNG, Hengeveld T, Postma FR, Moolenaar WH. Interaction of c-Src with gap junction protein connexin-43. Role in the regulation of cell-cell communication. J Biol Chem. 2001;276:8544-8549. (Pubitemid 37385669)
21. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett. 2002;518:154-158. (Pubitemid 34454983)
22. el-Fouly, MH, Trosko JE, Chang CC. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res. 1987;168:422-430.
23. Musil LS, Cunningham BA, Edelman GM, Goodenough DA. Differential phosphorylation of the gap junction protein connexin43 in junctional communication-competent and -deficient cell lines. J Cell Biol. 1990;111:2077-2088. (Pubitemid 20361313)
24. Sato H, Fukumoto K, Hada S, Hagiwara H, Fujimoto E, Negishi E, et al. Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. Cancer Chemother Pharmacol. 2007;60:449-457. (Pubitemid 46944588)
25. Un F. G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. Anticancer Drugs. 2007;18:411-417. (Pubitemid 46712404)
26. Wang JY, Naderi S, Chen TT. Role of retinoblastoma tumor suppressor protein in DNA damage response. Acta Oncol. 2001;40:689-695. (Pubitemid 33081976)
27. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004;3:796-803.
28. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res. 2007;13:433-444.
29. Song H, Sondak VK, Barber DL, Reid TJ, Lin J. Modulation of Janus kinase by cisplatin in cancer cells. Int Oncol. 2004;24: 1017-1026.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
31. Ali N, Yoshizumi M, Fujita Y, Izawa Y, Kanematsu Y, Ishizawa K, et al. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci. 2005;98:130-141.
32. Ali N, Yoshizumi M, Yano S, Sone S, Ohnishi H, Ishizawa K, et al. The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association. J Pharmacol Sci. 2006;102:112-120. (Pubitemid 44440974)
33. Kim R, Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer. 2007;101:2491-2502.
34. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Pääkkö P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res. 1999;5:3508-3515.
35. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol. 1998;275:L165-L171. (Pubitemid 28376238)
36. Yu J, Li X, Tashiro S, Onodera S, Ikejima T. Bcl-2 family proteins were involved in pseudolaric acid B-induced autophagy in murine fibrosarcoma L929 cells. J Pharmacol Sci. 2008; 107:295-302. (Pubitemid 352030316)